News | Treatment Planning | August 27, 2018

Tsuyama Chuo Proton Beam Center Treats First Patients With RayStation

Japanese center using Raystation treatment planning with Mitsubishi Electric proton therapy system for pencil beam scanning

Tsuyama Chuo Proton Beam Center Treats First Patients With RayStation

August 27, 2018 — Tsuyama Chuo Hospital in Okayama Prefecture, southwest Japan, has commenced clinical use of RayStation to plan pencil beam scanning (PBS) treatments at its Proton Beam Cancer Center. On May 15, the center carried out the world’s first patient treatment using RayStation together with Mitsubishi Electric’s proton therapy system, with a plan created in RayStation 6.

The proton center opened in 2016 and is run jointly with Okayama University. It is equipped with Mitsubishi Electric’s proton therapy system, featuring the Selectbeam nozzle, which supports both PBS and uniform scanning (US). Tsuyama Chuo Hospital has also expressed an interest in starting PBS treatments using multi-leaf collimator (MLC), following market clearance of Mitsubishi Electric’s MLC technique by Japanese authorities.

Yuki Tominaga, medical physicist at Tsuyama Chuo Proton Beam Center, said, "We are very pleased to have started PBS treatment safely using RayStation 6. In the future, we would like to establish comprehensive treatment combining PBS, US and photons with high-precision RayStation features such as multi-criteria optimization and deformable image registration."

Johan Löf, CEO of RaySearch, says: “We are delighted by this first clinical treatment with RayStation at Tsuyama Chuo Hospital. Proton therapy is a key focus area for RaySearch, and our goal for RayStation is to support as many treatment delivery platforms as possible. I look forward to a long and successful clinical cooperation.”

Tsuyama Chuo Hospital opened in 1951 and was the first general hospital in northern Okayama Prefecture. The Proton Beam Cancer Center opened in 2016 and is jointly operated with Okayama University Hospital. Both organizations have central roles in proton beam therapy, clinical research and education at the new facility.

RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines features such as multi-criteria optimization tools with full support for 4-D adaptive radiation therapy. It also includes functionality such as RaySearch’s algorithms for intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) optimization, and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability, according to the company.

For more information: www.raysearchlabs.com

Related Content

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product" report has been added to ResearchAndMarkets.com's offering. The prostate cancer nuclear medicine diagnostics market in the US was valued at $194.47M in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach $431.76M by 2027.

Getty Images

News | Prostate Cancer | January 13, 2021
January 13, 2021 — The ...
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021
January 11, 2021 — A study
Mirion Technologies, Inc., a global provider of innovative radiation detection and measurement solutions, announced that it has acquired Sun Nuclear Corporation. Sun Nuclear is the global leader in radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world.
News | Quality Assurance (QA) | January 08, 2021
January 8, 2021 — Mirion Technologies, Inc., a global provider of
RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular healthcare solutions in 2021 with the introduction of a compact shielding facility designed to accommodate the latest models of low energy, self-shielded linear accelerators (linacs) that are now available worldwide. 

Image courtesy of Siemens Healthineers

News | Linear Accelerators | January 04, 2021
January 4, 2021 — RAD Technology Medical Systems (RAD) ann
RaySearch Laboratories AB has launched the latest release of its widely adopted treatment planning system. RayStation 10B adds support for brachytherapy planning and a new GPU Monte Carlo algorithm, which typically cuts final dose computation times to less than five seconds.
News | Brachytherapy Systems | December 29, 2020
December 29, 2020 — RaySearch Laboratories AB has launched the latest release of its widely adopted treatment plannin
C-RAD has been selected as the partner to implement surface tracking technology for three proton cancer treatment centers in the U.S.
News | Proton Therapy | December 28, 2020
December 28, 2020 — C-RAD offers a specific version of its Catalyst System for use in...
According to recent studies, an increase in the COVID-19 positivity rate correlates to an increase in mortality from non-coronavirus-related diseases. This includes breast cancer, and researchers believe fear of contracting the virus compels patients to stay home instead of completing their post-lumpectomy radiotherapy regimens.

Image courtesy of Zeiss

News | Radiation Therapy | December 21, 2020
December 21, 2020 — According to recent studies, an increase in the...